Skip to main content
森萱医药 logo

森萱医药 — Investor Relations & Filings

Ticker · 920946 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 417 across all filing types
Latest filing 2022-03-28 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920946

About 森萱医药

https://www.senxuan.cn/

Jiangsu Senxuan Pharmaceutical Co., Ltd. specializes in the research, development, and production of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and specialized fine chemicals. The company’s product portfolio includes key intermediates for antiviral medications, such as those used in the treatment of HIV, and anticonvulsant agents like Primidone. Additionally, it produces high-purity chemical solvents including 1,4-dioxane and 1,3-dioxolane for diverse industrial applications. Senxuan Pharmaceutical maintains a focus on advanced chemical synthesis and large-scale manufacturing capabilities, adhering to international quality standards to support the global life sciences and chemical sectors. Its operations are characterized by a commitment to technical innovation and the supply of critical chemical building blocks for complex therapeutic formulations.

Recent filings

Filing Released Lang Actions
总经理工作细则
Board/Management Information Classification · 95% confidence The document is titled as the "General Manager Work Rules" of Jiangsu Senxuan Pharmaceutical Co., Ltd., and it details the internal management system, specifically the duties, appointment, and responsibilities of the general manager and other senior management. It includes governance and operational procedures but does not contain financial statements, audit results, or shareholder voting results. It is a detailed internal governance document related to management roles and responsibilities, not an announcement of a report or a regulatory filing. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or details about senior management and board-related matters. The document is substantive and over 5,000 characters, so it is not a mere announcement or report publication notice.
2022-03-28 Chinese
网络投票实施细则
Regulatory Filings Classification · 95% confidence The document is a detailed set of rules titled '江苏森萱医药股份有限公司网络投票实施细则' (Implementation Rules for Online Voting) issued by the company's board. It outlines procedures and regulations for shareholder voting via an online system, including preparation, voting rules, and legal compliance. There is no financial data, no report of financial results, no announcement of voting results, nor any indication of a meeting presentation or management changes. The document is a regulatory announcement about internal governance procedures related to shareholder voting mechanisms. It is not a report itself but a regulatory filing about company governance practices. Given the content and length (2543 characters), it fits best under Regulatory Filings (RNS) as it does not match other specific categories such as AGM materials, voting results, or management announcements.
2022-03-28 Chinese
累积投票制实施细则
Governance Information Classification · 95% confidence The document is a detailed announcement from Jiangsu Senxuan Pharmaceutical Co., Ltd. regarding the implementation rules of cumulative voting system for electing directors and supervisors. It includes procedural rules, nomination, election, and voting details, and is signed by the board of directors. There is no financial data, no mention of financial results, no audit information, no voting results announcement, and no indication of a meeting presentation or transcript. The document is a regulatory announcement about governance procedures, specifically about the cumulative voting system implementation rules, which is a governance-related internal rule. Therefore, the document fits best under Governance Information (CGR). The document length is under 5,000 characters and is not a report publication announcement or a certification. Hence, the classification is CGR with high confidence.
2022-03-28 Chinese
开源证券股份有限公司关于江苏森萱医药股份有限公司2021年度募集资金存放与使用情况的专项核查报告
Audit Report / Information Classification · 95% confidence The document is a detailed report on the use and management of funds raised by Jiangsu Senxuan Pharmaceutical Co., Ltd. in 2021. It includes specifics about the amount raised, the use of funds, compliance with regulatory requirements, and the results of a special inspection by the sponsoring securities company. The document references regulatory frameworks related to non-listed public companies and the Beijing Stock Exchange, and it provides a comprehensive review of fundraising activities, fund storage, and usage. This type of document is a specialized audit or inspection report focusing on fundraising and fund usage compliance, rather than a full annual report or earnings release. It is not a simple announcement or certification but a substantive report on fundraising fund management and compliance. Therefore, it fits best under the category of Audit Report / Information (AR).
2022-03-28 Chinese
开源证券股份有限公司关于江苏森萱医药股份有限公司2021年度公司治理情况专项核查报告
Governance Information Classification · 95% confidence The document is titled as a "2021年度公司治理情况专项核查报告" which translates to "2021 Annual Corporate Governance Special Inspection Report." It details the governance structure, board composition, internal controls, and compliance with regulations for the year 2021. The content focuses extensively on governance mechanisms, board and management qualifications, decision-making processes, and compliance with laws and regulations. There is no indication of financial statements, audit opinions, or earnings data. The document is a detailed report on corporate governance practices and compliance rather than a financial report or announcement. Therefore, it fits best under the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2022-03-28 Chinese
2021年度内部控制鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as an "内部控制鉴证报告" which translates to "Internal Control Assurance Report". It is issued by an accounting firm (天衡会计师事务所) and addresses the effectiveness of internal controls related to financial reporting for the fiscal year ending December 31, 2021. The content includes detailed evaluation of internal control systems, their design, testing, and conclusions on their effectiveness. It also references standards and regulatory frameworks for internal control evaluation. The document is over 10,000 characters, indicating it is a full report rather than a brief announcement. This type of document is a standalone audit-related report focusing on internal control over financial reporting, which fits the category of Audit Report / Information (AR). It is not an Annual Report (10-K) because it does not contain full financial statements or comprehensive company activity, nor is it a certification or a brief announcement. Therefore, the correct classification is AR with high confidence.
2022-03-28 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.